Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors

Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors (December 2020)

Monday, December 14, 2020
Webinar -- 11:00 AM CET
https://www.clinicaloptions.com/ESGO2020OvarianJoin1

Agenda

  • Consideration of patient-specific and disease-specific factors that influence the prioritization of different PARP inhibitors
  • Comparison of pharmacologic properties of approved and investigational PARPi
  • Role of PARPi maintenance therapy in newly diagnosed ovarian cancer
  • Genetic drivers of ovarian cancer development
  • PARP inhibitor-related adverse event identification and management
  • Future directions for PARPi therapy in frontline ovarian cancer

You must be a registrant of the European Society of Gynaecological Oncology (ESGO) State of the Art Conference 2020 Virtual Meeting in order to access this event.

Faculty

Faculty
Antonio González-Martín, MD, PhD

Head, Medical Oncology
Co-Director, Oncology Department
Oncology Department, Medical Oncology Service
Clinica Universidad Navarra
Madrid, Spain

Faculty
Ursula Matulonis, MD

Medical Director & Program Leader
Gynecologic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Faculty
Ignace Vergote, MD, PhD

Professor of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven, Belgium

This educational activity is not certified for CME/CE credit.

Goal Statement
The goal of this activity is to improve global learners’ knowledge and competence in applying practice-changing clinical data and expert recommendations to optimize the use of PARP inhibitors for the treatment of patients with ovarian cancer.

Target Audience
This program is intended for global gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess the improvement in risk of progression from the addition of PARP inhibitors in frontline treatment and how maintenance therapy can affect this improvement
  • Discuss patient and tumor characteristics that identify candidates for treatment with frontline PARP inhibitors
  • Describe the differences among the PARP inhibitors regarding dosing, administration, adverse events, and overall properties

Accreditation

This educational activity is not certified for CME/CE credit.